Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 4
1980 2
1981 1
1982 2
1983 2
1984 4
1985 1
1986 4
1987 1
1988 8
1989 2
1990 1
1991 5
1992 4
1993 6
1994 9
1995 11
1996 11
1997 18
1998 20
1999 18
2000 12
2001 8
2002 11
2003 13
2004 17
2005 11
2006 10
2007 7
2008 10
2009 9
2010 12
2011 12
2012 10
2013 8
2014 15
2015 10
2016 10
2017 12
2018 5
2019 7
2020 11
2021 12
2022 11
2023 7
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

370 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial.
Qu L, Liang X, Tian G, Zhang G, Wu Q, Huang X, Cui Y, Liu Y, Shen Z, Xiao C, Qin Y, Miao H, Zhang Y, Li Z, Ye S, Zhang X, Yang J, Cao G, Li Y, Yang G, Hu J, Wang X, Li Z, Li Y, Zhang X, Zhang G, Chen L, Hua W, Yu M, Lu C, Zhang X, Jiang H. Qu L, et al. Diabetes Care. 2021 Jun;44(6):1324-1333. doi: 10.2337/dc20-2109. Epub 2021 Apr 8. Diabetes Care. 2021. PMID: 33832957 Free PMC article. Clinical Trial.

The incidence of TAEs and GDs was significantly lower in the SZ-A group than the acarbose group (P < 0.01), but no differences for AEs or SAEs between the two groups were observed (P > 0.05). CONCLUSIONS: SZ-A exhibited equivalent hypoglycemic effects to acarbose

…

The incidence of TAEs and GDs was significantly lower in the SZ-A group than the acarbose group (P < 0.01), but no differences for

…
Effectiveness of dual combination therapy of acarbose plus metformin and acarbose plus myo-inositol in ameliorating the metabolic and endocrinologic complications of polycystic ovary syndrome - A randomized controlled trial.
Andavar M, Kamaraj R, Mahalingam Vijayakumar T, Murugesan A. Andavar M, et al. Eur J Obstet Gynecol Reprod Biol. 2024 Sep;300:6-11. doi: 10.1016/j.ejogrb.2024.07.001. Epub 2024 Jul 3. Eur J Obstet Gynecol Reprod Biol. 2024. PMID: 38972164 Clinical Trial.
AIM: The aim of the study is to determine and compare the effectiveness of acarbose plus metformin and acarbose plus myo-inositol combination therapy in alleviating the metabolic and endocrinologic complications of PCOS. ...Increase in serum progesterone and reducti …
AIM: The aim of the study is to determine and compare the effectiveness of acarbose plus metformin and acarbose plus myo-inosi …
A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
Wang W, Ning G, Ma J, Liu X, Zheng S, Wu F, Xu L, O'Neill EA, Fujita KP, Engel SS, Kaufman KD, Shankar RR. Wang W, et al. Curr Med Res Opin. 2017 Apr;33(4):693-699. doi: 10.1080/03007995.2016.1277200. Epub 2017 Jan 25. Curr Med Res Opin. 2017. PMID: 28035868 Clinical Trial.
OBJECTIVE: To evaluate the safety and efficacy of sitagliptin when added to the treatment of patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on acarbose monotherapy. RESEARCH DESIGN AND METHODS: This was a multicenter, randomized, placebo-cont …
OBJECTIVE: To evaluate the safety and efficacy of sitagliptin when added to the treatment of patients with type 2 diabetes mellitus (T2DM) a …
Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
Docherty KF, Jhund PS, Claggett B, Ferreira JP, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. Docherty KF, et al. JAMA Cardiol. 2021 Nov 1;6(11):1298-1305. doi: 10.1001/jamacardio.2021.2632. JAMA Cardiol. 2021. PMID: 34319398 Free PMC article. Clinical Trial.
Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
Cheng H, Zhang Z, Zhang B, Zhang W, Wang J, Ni W, Miao Y, Liu J, Bi Y. Cheng H, et al. Diabetes Care. 2022 May 1;45(5):1201-1210. doi: 10.2337/dc21-2064. Diabetes Care. 2022. PMID: 35263425 Clinical Trial.
Here, we investigated the therapeutic effects of liraglutide, dapagliflozin, or acarbose treatment on brain functional alterations and cognitive changes in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Thirty-six patients with type 2 diabetes inadequately con …
Here, we investigated the therapeutic effects of liraglutide, dapagliflozin, or acarbose treatment on brain functional alterations an …
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
Shen L, Dewan P, Ferreira JP, Cunningham JW, Jhund PS, Anand IS, Chandra A, Chiang LM, Claggett B, Desai AS, Gong J, Lam CSP, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Solomon SD, McMurray JJV. Shen L, et al. Circulation. 2024 Dec 10;150(24):1913-1927. doi: 10.1161/CIRCULATIONAHA.124.070553. Epub 2024 Oct 21. Circulation. 2024. PMID: 39429145 Clinical Trial.
Evaluation of the Bioequivalence of Acarbose in Healthy Chinese People.
Chen Y, Guo F, Wang X, Liu L, Yang C, Xiong Y, Zhang H. Chen Y, et al. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1225-1230. doi: 10.1002/cpdd.921. Epub 2021 Feb 19. Clin Pharmacol Drug Dev. 2021. PMID: 33606918 Free PMC article. Clinical Trial.
Two clinical trials with acarbose were conducted: study A, a pilot study (n = 12; 50 and 100 mg), and study B, a pivotal study (n = 60; 50 mg). In study A, there was a dose-dependent relationship between 50 mg acarbose and 100 mg acarbose and a significant di …
Two clinical trials with acarbose were conducted: study A, a pilot study (n = 12; 50 and 100 mg), and study B, a pivotal study (n = 6 …
Bioequivalence Evaluation Between Acarbose and Metformin Fixed-Dose Combination and Corresponding Individual Components in Healthy Chinese Male and Female Subjects.
Liu C, Cleton A, Sui Y, Liu Y, Li J, Yuan F, Sheng L, Xu H, Li X. Liu C, et al. Clin Pharmacol Drug Dev. 2022 Feb;11(2):173-184. doi: 10.1002/cpdd.994. Epub 2021 Jul 13. Clin Pharmacol Drug Dev. 2022. PMID: 34255938 Clinical Trial.
Acarbose and metformin have been recommended both as monotherapy and add-on therapy in type 2 diabetes mellitus. A novel fixed-dose combination (FDC) of acarbose and metformin has been developed to improve compliance and patient adherence to therapy. ...
Acarbose and metformin have been recommended both as monotherapy and add-on therapy in type 2 diabetes mellitus. A novel fixed-dose c …
Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
Clissold SP, Edwards C. Clissold SP, et al. Drugs. 1988 Mar;35(3):214-43. doi: 10.2165/00003495-198835030-00003. Drugs. 1988. PMID: 3286212 Review.
In comparative studies acarbose was significantly superior to placebo, and comparable to biguanides, when used alone or as an adjuvant to sulphonylurea therapy. ...The incidence of these reactions usually decreases with time. Thus, acarbose represents the first of a …
In comparative studies acarbose was significantly superior to placebo, and comparable to biguanides, when used alone or as an adjuvan …
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF. Derosa G, et al. Curr Med Res Opin. 2009 Mar;25(3):607-15. doi: 10.1185/03007990802711024. Curr Med Res Opin. 2009. PMID: 19232035 Clinical Trial.
OBJECTIVE: To compare the metabolic effects of acarbose and repaglinide in type 2 diabetic patients who are being treated with a sulphonylurea-metformin combination therapy. ...RESULTS: Seven patients did not complete the study, comprising one patient who was lost to follo …
OBJECTIVE: To compare the metabolic effects of acarbose and repaglinide in type 2 diabetic patients who are being treated with a sulp …
370 results